Comparative Pharmacology
Head-to-head clinical analysis: CYCLOCORT versus SERNIVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOCORT versus SERNIVO.
CYCLOCORT vs SERNIVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
Apply a thin layer to affected area twice daily for up to 2 weeks.
None Documented
None Documented
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Approximately 3 hours (parent drug); clinical duration extended via formulation.
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid